Back to News
May 11, 2026 12:10 AM

Kelyniam Global Announces Strong Q1 2026 Financial Results

CANTON, Conn., May 11, 2026 /PRNewswire/ -- Kelyniam Global (OTC:KLYG), a leader in custom cranial implants, today reported its financial results for the first quarter ended March 31, 2026. The company delivered excellent performance, with strong revenue growth and clear improvement in profitability.

Q1 Financial Highlights (Compared to Q1 2025)

Total revenue reached $1,150,130, an 84% increase from $624,910.

Gross profit rose to $962,814, compared to $470,490, a 105% increase.

Income from operations improved to $295,295, compared to an operating loss of $(140,556)

"We are very pleased with our strong start in 2026," said Ross Bjella, CEO. "These results reflect the hard work of our team and the growing demand for our regenerative product line."

Sales of CustomizedBone™ implants, licensed from Finceramica, grew more than 50% ...